On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.
Weill Cornell Medicine receives NIH grant to lead a national contraceptive research center
Weill Cornell Medicine has received a three-year, nearly $6 million grant to lead one of three national contraceptive research centers.
September 21, 2023